On Tuesday, Shares of Aquinox Pharmaceuticals Inc (NASDAQ:AQXP), gained 11.28% to $21.01.
Aquinox Pharmaceutical, released its second quarter 2015 financial results showing a net loss EPS of $(0.49) as compared to estimates of $(0.44). This positive news accompanied by positive mid-trial results from its AQX-1125 drug candidate, sent the stock soaring nearly 2000%.
The jump in share price was likely a result of the low float in the stock structure and the heavy buying from institutional investors counting Bake Brothers Investments who raised their stake in the company to 40%. Large drug maker also showed interest in the company filing SEC reports indicating a stake in the company. This rocket will certainly be news driven for the next several months as investors have had their eyes turned towards the stock.
Aquinox Pharmaceuticals Inc., a clinical-stage pharmaceutical company, engages in discovering and developing targeted therapeutics for diseases in the areas of inflammation and immuno-oncology.
Shares of CDW Corp (NASDAQ:CDW), inclined 0.25% to $39.39, during its last trading session.
CDW Corporation, declared second quarter 2015 results, a cash dividend to be paid in September 2015, and the acquisition of UK-based IT solutions provider Kelway.
Second Quarter of 2015 Highlights:
Total net sales in the second quarter of 2015 were $3.314 billion, contrast to $3.106 billion in the second quarter of 2014, an enhance of 6.7 percent. Total net sales growth in constant currency as compared to second quarter 2014 was 7.2 percent, as Canadian sales were negatively influenced by currency translation. Average daily sales in the second quarter of 2015 were $51.8 million, contrast to $48.5 million in the second quarter of 2014. There were 64 selling days in both the second quarters of 2015 and 2014.
Total Corporate segment net sales in the second quarter of 2015 were $1.761 billion, 6.3 percent higher than the second quarter of 2014. Corporate average daily sales in the second quarter of 2015 were $27.5 million, contrast to $25.9 million in the second quarter of 2014. Corporate results reflected a 7 percent sales enhance to Medium and Large customers and a 3 percent sales enhance to Small Business customers.
- Total Public segment net sales in the second quarter of 2015 were $1.374 billion, 8.1 percent higher than the second quarter of 2014. Public average daily sales in the second quarter of 2015 were $21.5 million, contrast to $19.9 million in the second quarter of 2014. Public results were led by a sales enhance of almost 23 percent to Government customers. Education sales raised 4 percent and Healthcare sales raised 3 percent.
- Net sales for CDW’s Advanced Services business and Canadian operations, combined as “Other” for financial reporting purposes, remained relatively flat at $178.4 million in the second quarter of 2015, contrast to $178.2 million in the second quarter of 2014. Mid-teens growth in Advanced Services was offset by a decline in US dollar-denominated Canadian sales. Canadian sales in local currency raised high-single digits. “Other” average daily sales in the second quarter of 2015 and 2014 were $2.8 million. CDW’s Advanced Services business comprises of customized engineering services delivered by CDW professional engineers and managed services, counting hosting and data center services.
CDW Corporation distributes information technology (IT) solutions in the United States and Canada. It operates in two segments, Corporate and Public. The company offers discrete hardware and software products to integrated IT solutions, counting mobility, security, data center optimization, cloud computing, virtualization, and collaboration.
Finally, Eagle Pharmaceuticals Inc (NASDAQ:EGRX), ended its last trade with -16.74% loss, and closed at $79.22.
Eagle Pharmaceuticals, declared its financial results for the three- and six-month periods ended June 30, 2015. Highlights of and subsequent to the second quarter of 2015 comprise:
- The U.S. Food and Drug Administration (“FDA”) accepted for filing the New Drug Application (“NDA”) for Eagle’s bendamustine hydrochloride (HCl) rapid infusion product (the “rapid infusion” product) for the treatment of patients with chronic lymphocytic leukemia (“CLL”) and patients with indolent B-cell non-Hodgkin lymphoma (“NHL”) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regime. The FDA action date for this NDA under the Prescription Drug User Fee Act (“PDUFA”) is December 13, 2015;
- The FDA accepted for filing the NDA for Eagle’s unique, ready-to-use, liquid bivalirudin (“RTU bivalirudin”) for the treatment of patients: undergoing percutaneous coronary intervention (“PCI”) with use of glycoprotein IIb/IIIa inhibitor, undergoing PCI with, or at risk of, heparin-induced thrombocytopenia and thrombosis syndrome, and/or with unstable angina undergoing percutaneous transluminal coronary angioplasty (“PTCA”). The FDA action date for this NDA under PDUFA is March 19, 2016;
- The U.S. Patent and Trademark Office granted two new patents pertaining to the rapid infusion bendamustine product, both extending to March 2033;
- RYANODEX (dantrolene sodium) for Injectable Suspension was granted seven years of U.S. market exclusivity for the treatment of malignant hyperthermia (“MH”) by the FDA;
- Advanced plans to conduct a clinical trial of RYANODEX for the treatment of exertional heat stroke, a potential new indication, in September 2015 in Saudi Arabia;
- Product sales raised to $3.7 million contrast to $0.4 million for the second quarter of 2014;
- Total revenue was $6.0 million contrast to $5.8 million for the second quarter of 2014;
- Net loss was $(8.2) million, or $(0.53) per basic and diluted share, contrast to a net loss attributable to common stockholders of $(2.9) million, or $(0.21) per basic and diluted share, for the second quarter of 2014; and
- Cash, cash equivalents and short-term investments were $103.7 million at June 30, 2015.
Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
